$REFR
RESEARCH FRONTIERS INC Stock $refr

$refr Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223015427 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$185.0K	$248.2K	$173.8K
YoY Change	116.39%	42.77%	-17.22%
Cost Of Revenue	$564.7K	$587.8K	$600.7K
YoY Change	-17.23%	-2.15%	-4.65%
Gross Profit	-$379.7K	-$339.6K	-$426.9K
YoY Change	-36.38%	-20.44%	4.11%
Gross Profit Margin	-205.17%	-136.85%	-245.57%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$145.6K	$149.2K	$148.8K
YoY Change	-0.56%	0.26%	-0.78%
% of Gross Profit
Depreciation & Amortization	$6.840K	$6.820K	$100.00
YoY Change	-52.2%	6720.0%
% of Gross Profit
Operating Expenses	$145.6K	$737.0K	$148.8K
YoY Change	-82.43%	395.24%	6.3%
Operating Profit	-$525.3K	-$488.8K	-$575.7K
YoY Change	-29.32%	-15.09%	4.67%
Interest Expense	$31.61K	$26.21K	-$52.65K
YoY Change	2294.7%	-149.78%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$493.7K	-$462.6K	-$628.4K
YoY Change	-33.46%	-26.37%	12.21%
Income Tax
% Of Pretax Income
Net Earnings	-$493.7K	-$462.6K	-$628.4K
YoY Change	-33.46%	-26.37%	12.21%
Net Earnings / Revenue	-266.78%	-186.42%	-361.47%
Basic Earnings Per Share	-$0.01	-$0.01	-$0.02
Diluted Earnings Per Share	-$0.01	-$0.01	-$19.85K
COMMON SHARES
Basic Shares Outstanding	33.51M shares	33.51M shares	31.65M shares
Diluted Shares Outstanding	33.51M shares	33.29M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.518M	$4.140M	$2.466M
YoY Change	85.14%	67.88%	-41.56%
Cash & Equivalents	$3.518M	$1.152M	$2.466M
Short-Term Investments	$0.00	$2.988M	$0.00
Other Short-Term Assets	$231.8K	$93.19K	$86.57K
YoY Change	-1.53%	7.65%	-3.81%
Inventory
Prepaid Expenses
Receivables	$666.2K	$683.9K	$753.6K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.416M	$4.918M	$3.307M
YoY Change	72.35%	48.72%	-34.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$303.2K	$59.27K	$519.9K
YoY Change	280.88%	-88.6%	-24.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$56.07K	$56.07K	$33.57K
YoY Change	67.04%	67.01%	11.9%
Total Long-Term Assets	$359.3K	$401.9K	$553.4K
YoY Change	-29.55%	-27.38%	-24.19%
TOTAL ASSETS
Total Short-Term Assets	$4.416M	$4.918M	$3.307M
Total Long-Term Assets	$359.3K	$401.9K	$553.4K
Total Assets	$4.775M	$5.319M	$3.860M
YoY Change	55.43%	37.81%	-33.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$45.79K	$25.44K	$16.02K
YoY Change	44.46%	58.8%	-59.95%
Accrued Expenses	$227.3K	$46.73K	$261.0K
YoY Change	266.13%	-82.09%	8.73%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$285.9K	$283.8K	$287.7K
YoY Change	-1.74%	-1.38%	-7.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$163.8K	$216.9K	$416.6K
YoY Change	-55.38%	-47.93%	-30.56%
Total Long-Term Liabilities	$163.8K	$216.9K	$416.6K
YoY Change	-55.38%	-47.93%	-30.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$285.9K	$283.8K	$287.7K
Total Long-Term Liabilities	$163.8K	$216.9K	$416.6K
Total Liabilities	$449.7K	$500.7K	$704.3K
YoY Change	-31.67%	-28.91%	-22.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$123.3M	-$122.8M
YoY Change	1.82%
Common Stock	$127.6M	$127.6M
YoY Change	3.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.325M	$4.800M	$3.156M
YoY Change
Total Liabilities & Shareholders Equity	$4.775M	$5.319M	$3.860M
YoY Change	55.43%	37.81%	-33.1%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$493.7K	-$462.6K	-$628.4K
YoY Change	-33.46%	-26.37%	12.21%
Depreciation, Depletion And Amortization	$6.840K	$6.820K	$100.00
YoY Change	-52.2%	6720.0%
Cash From Operating Activities	-$625.8K	-$597.1K	-$498.0K
YoY Change	7.56%	19.92%	-22.2%
INVESTING ACTIVITIES
Capital Expenditures	$600.00	$702.00	-$610.00
YoY Change	-230.43%	-215.08%
Acquisitions
YoY Change
Other Investing Activities	$2.992M	-$2.965M	$2.695M
YoY Change		-210.03%
Cash From Investing Activities	$2.991M	-$2.966M	$2.694M
YoY Change	-650302.17%	-210.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$484.5K
YoY Change
NET CHANGE
Cash From Operating Activities	-625.8K	-$597.1K	-498.0K
Cash From Investing Activities	2.991M	-$2.966M	2.694M
Cash From Financing Activities	0.000	$484.5K
Net Change In Cash	2.365M	-$3.078M	$0.00
YoY Change	-506.18%		-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$625.8K	-$597.1K	-$498.0K
Capital Expenditures	$600.00	$702.00	-$610.00
Free Cash Flow	-$626.4K	-$597.8K	-$497.3K
YoY Change	7.75%	20.2%	-22.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000793524
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss		usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Entity File Number EntityFileNumber	000-14893
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	RESEARCH FRONTIERS INCORPORATED
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2103466
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	240 CROSSWAYS PARK DRIVE
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	WOODBURY
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11797-2033
CY2023Q1	dei	City Area Code CityAreaCode	516
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	364-1902
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Trading Symbol TradingSymbol	REFR
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33509287	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1152433	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4230916	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2988060	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1153450	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1158450	usd
CY2023Q1	REFR	Royalties Receivable Net Current RoyaltiesReceivableNetCurrent	683863	usd
CY2022Q4	REFR	Royalties Receivable Net Current RoyaltiesReceivableNetCurrent	589599	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	93188	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	100973	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	4917544	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4921488	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59274	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65388	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	286551	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	323509	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56066	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56066	usd
CY2023Q1	us-gaap	Assets Assets	5319435	usd
CY2022Q4	us-gaap	Assets Assets	5366451	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	199672	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	196405	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	25440	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	71079	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46730	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34379	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	11921	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	283763	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	301863	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	216943	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	267723	usd
CY2023Q1	us-gaap	Liabilities Liabilities	500706	usd
CY2022Q4	us-gaap	Liabilities Liabilities	569586	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33509287	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33509287	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33150396	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33150396	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	3351	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3315	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	127634493	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	127150027	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122819115	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122356477	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4818729	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4796865	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5319435	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5366451	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	248175	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	173828	usd
CY2023Q1	us-gaap	Other General Expense OtherGeneralExpense	587799	usd
CY2022Q1	us-gaap	Other General Expense OtherGeneralExpense	600698	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	149222	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	148825	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	737021	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	749523	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-488846	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-575695	usd
CY2023Q1	REFR	Net Investment Income Loss NetInvestmentIncomeLoss	26208	usd
CY2022Q1	REFR	Net Investment Income Loss NetInvestmentIncomeLoss	-52653	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-462638	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-628348	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33286648	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31650396	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3783923	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-628348	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	3155575	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4796865	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4796865	usd
CY2023Q1	REFR	Stock Issued During Period Value Stock Warrants Of Exercised StockIssuedDuringPeriodValueStockWarrantsOfExercised	484502	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-462638	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4818729	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4818729	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-462638	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-628348	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6816	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7180	usd
CY2022Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-60143	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	22900	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	36958	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	36351	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-5000	usd
CY2023Q1	REFR	Increase Decrease In Royalty Receivable IncreaseDecreaseInRoyaltyReceivable	89264	usd
CY2022Q1	REFR	Increase Decrease In Royalty Receivable IncreaseDecreaseInRoyaltyReceivable	-78086	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7785	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6358	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-33288	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-25045	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	11921	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	10756	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-47513	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-43435	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-597123	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-497954	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	702	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	605	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2965160	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2694968	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2965862	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2694363	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	484502	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	484502	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3078483	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2196409	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4230916	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	269964	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1152433	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2466373	usd
CY2023Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_80E_eus-gaap--BasisOfAccounting_z96294SAqkfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Note 1. <span id="xdx_824_zZuDcxKFsXb6">Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023. The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date. For further information, refer to the consolidated financial statements and footnotes thereto included in the Annual Report on Form 10-K relating to Research Frontiers Incorporated for the fiscal year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain amounts in the accompanying March 31, 2022 condensed consolidated statements of cash flows have been reclassified to conform to the March 31, 2023 presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_z6HLTmN9rW63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Note 2. <span id="xdx_82F_zlwnwx8erAi5">Business</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research Frontiers Incorporated (“Research Frontiers” or the “Company”) operates in a single business segment which is engaged in the development and marketing of technology and devices to control the flow of light. Such devices, often referred to as “light valves” or suspended particle devices (“SPDs”), use colloidal particles that are either incorporated within a liquid suspension or a film, which is usually enclosed between two sheets of glass or plastic having transparent, electrically conductive coatings on the facing surfaces thereof. At least one of the two sheets is transparent. SPD technology, made possible by a flexible light-control film invented by Research Frontiers, allows the user to instantly and precisely control the shading of glass/plastic manually or automatically. SPD technology has numerous product applications, including SPD-Smart™ windows, sunshades, skylights and interior partitions for homes and buildings; automotive windows, sunroofs, sun visors, sunshades, rear-view mirrors, instrument panels and navigation systems; aircraft windows; museum display panels; eyewear products; and flat panel displays for electronic products. SPD-Smart light control film is now being developed for, or used in, architectural, automotive, marine, aerospace and appliance applications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has primarily utilized its cash, cash equivalents, and investments generated from sales of our common stock, proceeds from the exercise of options and warrants, and royalty fees collected to fund its research and development of SPD light valves, for marketing initiatives, and for other working capital purposes. The Company’s working capital and capital requirements depend upon numerous factors, including the results of research and development activities, competitive and technological developments, the timing and cost of patent filings, and the development of new licensees and changes in the Company’s relationships with its existing licensees. The degree of dependence of the Company’s working capital requirements on each of the foregoing factors cannot be quantified; increased research and development activities and related costs would increase such requirements; the addition of new licensees may provide additional working capital or working capital requirements; and changes in relationships with existing licensees would have a favorable or negative impact depending upon the nature of such changes. We have incurred recurring losses since inception and expect to continue to incur losses as a result of costs and expenses related to our research and continued development of our SPD technology and our corporate general and administrative expenses. Our capital requirements and operations to date have been substantially funded through sales of our common stock, exercise of options and warrants and royalty fees collected. As of March 31, 2023, we had working capital of approximately $<span id="xdx_90F_ecustom--WorkingCapital_iI_pn5n6_c20230331_zPHcSxFXa1Al" title="Working capital">4.6</span> million, cash and cash equivalents and marketable securities of approximately $<span id="xdx_907_ecustom--CashAndCashEquivalentsAndMarketableSecurities_iI_pn5n6_c20230331_zS9X1brARG73" title="Cash and cash equivalents and marketable securities">4.1 </span>million, shareholders’ equity of approximately $<span id="xdx_909_eus-gaap--StockholdersEquity_iI_pn5n6_c20230331_z60kWkrwPCb5" title="Shareholders' equity">4.8</span> million and an accumulated deficit of approximately $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230331_zAqY03TcUca2" title="Accumulated deficit">122.8 </span>million. Our projected cash flow shortfall based on our current operations adjusted for any non-recurring cash expenses and adjusted for additional royalties expected to be received for use of our products in new production for the next 12 months is approximately $<span id="xdx_907_ecustom--NonrecurringCashExpenses_c20230101__20230331__srt--RangeAxis__srt--MinimumMember_zkly6xCRAe0c" title="Non-recurring cash expenses">200,000</span> to $<span id="xdx_90C_ecustom--NonrecurringCashExpenses_c20230101__20230331__srt--RangeAxis__srt--MaximumMember_zjNC6st61Jaf" title="Non-recurring cash expenses">250,000</span> per quarter. Based on our current expectations of our cash flow shortfall for the next 12 months, our working capital would support our activities for at least the next 12 months from the issuance of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event that we are unable to generate sufficient cash from our operating activities or raise additional funds, we may be required to delay, reduce or severely curtail our operations or otherwise impede our on-going business efforts, which could have a material adverse effect on our business, operating results, financial condition and long-term prospects. The Company may seek to obtain additional funding through future equity issuances. There can be no assurance as to the availability or terms upon which such financing and capital might be available. The eventual success of the Company and generation of positive cash flow will be dependent upon the commercialization of products using the Company’s technology by the Company’s licensees and payments of continuing royalties on account thereof. To date, the Company has not generated sufficient revenue from its licensees to fund its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent Global Events:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 11, 2020, the World Health Organization declared the novel strain of coronavirus (“COVID-19”) a global pandemic and recommended containment and mitigation measures worldwide.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2020 revenues have been negatively impacted from the pandemic due to delays in manufacture of products using our technology. Most of the products using our technology are manufactured by licensees overseas in Europe and Asia who have been similarly affected by the pandemic. The disruption caused by public health crises, such as COVID-19, could result in lower levels of sale activity for products using our technology resulting in lower level of royalties owed to us from the sale of these products. The duration of the potential business disruptions and related financial impact cannot be reasonably estimated at this time, but could materially adversely affect our business, financial condition, results of operations, and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	REFR	Working Capital WorkingCapital	4600000	usd
CY2023Q1	REFR	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	4100000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4800000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122800000	usd
CY2023Q1	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	125000	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2000000.0	shares
CY2022Q3	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	2.30
CY2022Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	4600000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3450000	usd
CY2022Q3	REFR	Proceeds From Expects To Receive Remaining Amount ProceedsFromExpectsToReceiveRemainingAmount	1150000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2541100	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1246960	shares
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.055	pure
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	54000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	163000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	222000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	56000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	441000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	24385	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	416615	usd
CY2022Q1	us-gaap	Marketable Securities MarketableSecurities	0	usd
CY2022Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-60143	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	22900	usd
CY2023Q1	REFR	Investment Treasury Bill InvestmentTreasuryBill	3000000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-015427-index-headers.html	Edgar Link	pending
0001493152-23-015427-index.html	Edgar Link	pending
0001493152-23-015427.txt	Edgar Link	pending
0001493152-23-015427-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
refr-20230331.xsd	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
refr-20230331_cal.xml	Edgar Link	unprocessable
refr-20230331_def.xml	Edgar Link	unprocessable
refr-20230331_lab.xml	Edgar Link	unprocessable
refr-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REFR
RESEARCH FRONTIERS INC Stock $refr

2023 Q2 Form 10-Q Financial Statement

#000149315223015427 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REFR RESEARCH FRONTIERS INC Stock $refr

2023 Q2 Form 10-Q Financial Statement

#000149315223015427 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REFR
RESEARCH FRONTIERS INC Stock $refr